How Important Are Hematological Parameters in the Prognosis of Severe Covid-19 Patients?

NCT05650944 | Completed

• 1 other identifier: HisarIH-125
• Study Type: observational
• Target: 125
• Locations: 1 country
• Sites: 1

Brief Summary

It is aimed to reveal the treatment and prognostic values by evaluating the differences in hematological parameters and indices, especially in dead Covid-19 cases. Material Method: It is planned to retrospectively examine the hemogram parameters of 125 male, 44 female and 169 critical Covid-19 patients hospitalized between 01.03.2020 and 31.12.2021. Subjects were divided into 2 groups as deceased (77) and living (92) patients according to demographic data such as age and gender. Statistical evaluation: All analyzes were SPSS 25.0, Kolmogorov Smirnov test was used to determine distribution, median and interquartile range (Tukey's Hinges Percentile) were used to summarize variables. The differences between the Independent-Samples Mann Whitney U Test and the data of the patient groups and the optimal cut-off values, sensitivity and specificity values will be determined by ROC analysis. It will be considered statistically significant when the p value is below 0.05 (with the two-tailed test)

Conditions

COVID-19

Keywords

Hemogram; NLR; MPV/PLT; MPV/PCT

Outcome Measures

Primary Outcomes (1)

• Hematological parameters in the prognosis of severe Covid-19 patients.

  Hemogram values of the deceased and surviving patients participating in the study were compared.

  2020-2021

Study Arms (2)

Covid-19 Survivor groups

Covid-19 survivor groups are hematological parameters

Diagnostic Test: Hemogram

Covid-19 Non-survivor groups

Hematological parameters in patients with severe COVID-19 who have died.

Diagnostic Test: Hemogram

Interventions

Hemogram DIAGNOSTIC_TEST

Sysmex XN-1000 hematological analyzer

Covid-19 Non-survivor groups; Covid-19 Survivor groups

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study had 169 patients in all, including 44 women and 125 males

You may qualify if:

• Patients over the age of 18
• Critical patients taken to intensive care
• The length of stay in the ICU is more than 24 hours

You may not qualify if:

• \) Patients under 18 years of age (2) Patients with hematological malignancies (3) The length of stay in the ICU is less than 24 hours.

Sponsors & Collaborators

• Hisar Intercontinental Hospital: lead

Study Sites (1)

Hisar Hospital Intercontinental

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Ramazan Gozukucuk

  Istanbul Galata Universty

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 2, 2022
• First Posted: December 14, 2022
• Study Start: March 1, 2020
• Primary Completion: December 31, 2021
• Study Completion: September 30, 2022
• Last Updated: December 14, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Between 1 March 2020 and 31 December 2021
• Access Criteria: All of result open accses.

Locations

TU (1)